Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Net Income towards Common Stockholders (2020 - 2025)

Historic Net Income towards Common Stockholders for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $2.9 million.

  • Mirum Pharmaceuticals' Net Income towards Common Stockholders rose 12040.74% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.4 million, marking a year-over-year increase of 5849.86%. This contributed to the annual value of -$87.9 million for FY2024, which is 4618.49% up from last year.
  • Mirum Pharmaceuticals' Net Income towards Common Stockholders amounted to $2.9 million in Q3 2025, which was up 12040.74% from -$5.9 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' 5-year Net Income towards Common Stockholders high stood at $57.3 million for Q4 2021, and its period low was -$74.0 million during Q2 2023.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$27.1 million (2022), whereas its average is -$25.7 million.
  • In the last 5 years, Mirum Pharmaceuticals' Net Income towards Common Stockholders surged by 25352.45% in 2021 and then crashed by 17299.14% in 2023.
  • Over the past 5 years, Mirum Pharmaceuticals' Net Income towards Common Stockholders (Quarter) stood at $57.3 million in 2021, then tumbled by 163.6% to -$36.4 million in 2022, then increased by 2.12% to -$35.7 million in 2023, then skyrocketed by 33.28% to -$23.8 million in 2024, then skyrocketed by 112.21% to $2.9 million in 2025.
  • Its Net Income towards Common Stockholders stands at $2.9 million for Q3 2025, versus -$5.9 million for Q2 2025 and -$14.7 million for Q1 2025.